ecleralimab
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 29, 2017 (NCT03138811)
Timeline
Indications
Mechanism of action
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- csj117
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04882124 | Phase 2 | Sep 24, 2021 | Novartis |
| NCT04946318 | Phase 2 | Sep 9, 2021 | Novartis |
| NCT04410523 | Phase 2 | Jul 31, 2020 | Novartis |
| NCT03138811 | Phase 1 | Sep 29, 2017 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1